NACTN study gains momentum

Posted by Reeve Staff in Daily Dose on September 09, 2016 # Research

The Christopher & Dana Reeve Foundation's North American Clinical Trials Network (NACTN), with funding from the Department of Defense (DOD), is partnering with AOSpine North America in RISCIS (Riluzole in Spinal Cord Injury Study). The Phase II/III clinical trial is a multi-center, randomized, placebo-controlled double-blinded study that will enroll 351 patients with acute cervical spinal cord injuries. The DOD funding also enables NACTN sites to conduct a RISCIS sub-study, the pharmacology of riluzole, to determine optimal dosage of the drug.

Learn more by visiting our Research page.

This project was supported, in part, by grant number 90PRRC0002, from the U.S. Administration for Community Living, Department of Health and Human Services, Washington, D.C. 20201. Grantees undertaking projects under government sponsorship are encouraged to express freely their findings and conclusions. Points of view or opinions do not, therefore, necessarily represent official Administration for Community Living policy.